Gilead Sciences Secures CHMP Support for Trodelvy Plus KEYTRUDA
FOSTER CITY, Calif., July 24, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
KEYTRUDA
Advertisement
Alpha Tau Medical Ltd. Reports Positive Head and Neck Cancer Results
JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...
Almirall Seeks EMA Approval to Expand Ebglyss Use in Kids
BARCELONA, Spain, July 17, 2026 Almirall S.A. has announced that the European Medicines Agency (EMA) has accepted the Marketing...
Marengo Earns ESMO Oral Slot for Phase II Cancer Data
CAMBRIDGE, Mass., July 20, 2026 Marengo Therapeutics has announced that updated Phase II clinical data from its investigational immunotherapy...
Evaxion Highlights Phase 2 EVX-01 Melanoma Results
Copenhagen, Denmark, July 17, 2026 Evaxion A/S announced that it will present three-year clinical efficacy data from its Phase...
Advertisements
Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Immutep Reports Positive INSIGHT-003 Survival Data
SYDNEY, Australia, July 13, 2026 Immutep announced positive mature overall survival data from its investigator-initiated Phase 1 INSIGHT-003 trial...
LEO Pharma Reports Positive Phase 2 Tralokinumab Results
BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Pfizer Canada Secures PADCEV Plus KEYTRUDA Approval
KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...
Advertisement
